UB-VV111

UB-VV111 is an investigational gene therapy designed to generate CD19-directed chimeric antigen receptor (CAR) T cells in vivo for the treatment of hematologic malignancies. It utilizes a third-generation, self-inactivating, replication-incompetent lentiviral vector (LVV) with a surface-engineered viral envelope pseudotyped with cocal virus fusion glycoprotein and a membrane-bound multidomain fusion (MDF) protein. The vector encodes two key components: an anti-CD19 CAR (comprising an FMC63 single-chain variable fragment and 4-1BB/CD3ζ intracellular signaling domains) and a rapamycin-activated cytokine receptor (RACR), which is designed to enhance the enrichment and expansion of engineered CAR T cells in vivo via STAT5 signaling. This approach aims to overcome limitations of traditional ex vivo CAR-T therapies by enabling direct in situ generation of therapeutic CAR T cells within the patient’s body, potentially eliminating the need for lymphodepletion or complex cell manufacturing processes. UB-VV111 is being developed primarily for B-cell malignancies such as large B-cell lymphoma and chronic lymphocytic leukemia[2][3][6][7].